Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “breast-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 272
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 272 pipeline programs matching "breast-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

272 results for “breast-cancer” Back to intelligence hub

Search results

Page 11 of 12
  1. SPARC1613

    Advanced Accelerator Applications

    Recurrent or Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial
  2. SZ011 CAR-NK

    The First People's Hospital of Lianyungang

    Advanced Triple Negative Breast Cancer

    phase 1 small molecule active

    1 trial
  3. TTI-101

    Tvardi Therapeutics

    Breast Cancer

    phase 1 small molecule completed

    2 trials
  4. Trastuzumab

    Hoffmann-La Roche

    Early Breast Cancer

    phase 1 small molecule completed

    1 trial
  5. Vantictumab combined with paclitaxel

    Mereo BioPharma Group plc

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial
  6. interleukin-4 PE38KDEL cytotoxin

    NEUROCRINE BIOSCIENCES INC

    Breast Cancer

    phase 1 mab completed

    1 trial
  7. limonene containing massage oil

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 1 other completed

    1 trial
  8. Abemaciclib

    Eli Lilly and Company

    Metastatic Breast Cancer

    approved small molecule terminated

    1 trial
  9. Dexmedetomidine

    Peking University Third Hospital

    Breast Cancer

    approved small molecule completed

    1 trial
  10. Dexmedetomidine

    United Therapeutics Europe Ltd

    Breast Cancer

    approved small molecule active

    1 trial
  11. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule completed

    1 trial
  12. OBU-BC-II-206

    The First People's Hospital of Lianyungang

    HER2 Positive Breast Cancer

    approved small molecule active

    1 trial
  13. Pegylated liposomal doxorubicin

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial
  14. Ribociclib

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    approved small molecule active

    1 trial
  15. Trastuzumab Rezetecan

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial
  16. docetaxel

    Hoffmann-La Roche

    Breast Cancer

    approved small molecule completed

    2 trials
  17. silk suture

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    approved other completed

    1 trial
  18. 89Zr-trastuzumab

    United Therapeutics Europe Ltd

    Breast Cancer Metastases

    other completed

    1 trial
  19. Accelerated partial breast irradiation

    Universal Integrated

    Breast Cancer

    other active

    1 trial
  20. Albumin paclitaxel/neutrophil drug

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    mab active

    1 trial
  21. Biobran supplementation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer Stages I

    other active

    1 trial
  22. Boost to the tumour bed

    United Therapeutics Europe Ltd

    Early Breast Cancer

    other active

    1 trial
  23. Breast MRI interpretation

    The First People's Hospital of Lianyungang

    Breast Cancer

    other active

    1 trial
  24. Carbon Nanoparticle Suspension Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.